ERBB2 and breast carcinoma: The ASCO breast cancer guidelines [15] recommend that clinicians may use Oncotype DX, MammaPrint, Breast Cancer Index (BCI), and EndoPredict to guide adjuvant endocrine and chemotherapy in patients who are postmenopausal (or aged 50 years and older if the menopausal status is unknown) with early-stage ER+ , HER2– breast cancer that is node-negative or with 1–3 positive nodes.